PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma

The histone deacetylase inhibitor (HDACi), panobinostat (Pano), is approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treatment of relapsed/refractory multiple myeloma (MM). Despite regulatory approvals, Pano is used on a limited basis in MM due...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Reeder M., Basar, Ashton P., Reyes, Leticia, Duncan, Ravyn M., Li, Hong, Dolloff, Nathan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054865/
https://www.ncbi.nlm.nih.gov/pubmed/35381875
http://dx.doi.org/10.1007/s00280-022-04425-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054865/
https://www.ncbi.nlm.nih.gov/pubmed/35381875
http://dx.doi.org/10.1007/s00280-022-04425-3

Ejemplares similares